TRIUMPH

Check-in as promised in the title: 10 months in and dose escalation is still the thing I get wrong. 10 months. Those are measured, not estimated, and not rounded up in…

unpopular opinion: most of what gets said here about phase 2 is guesswork. Change my mind, genuinely — I have no stake in being right about this. The standing caveat,…

Short version of the title, which is already short: WXT reta — PeptideMeter came back 97.7% against a claimed 97.0%. Longer version underneath. Pulling the figures out…

57 weeks, 25kg, and glucagon was the hard part, logged the same way every week so the comparison is at least internally fair. Hard numbers: 57 weeks and 25kg. Anything…

week 19 check-in — 9kg down, early fullness manageable, one thing confusing me, logged the same way every week so the comparison is at least internally fair. The…

Check-in as promised in the title: 45 weeks on 0.25mg, full numbers, ask me anything boring. The numbers the title promised, since a headline without them is worthless:…

unpopular opinion: most of what gets said here about hazard ratio is guesswork, which sounds obvious until you try to state the evidence for it. Went looking for the…

small win: triple agonist stopped being a problem at week 65, and the part I actually want to talk about is at the bottom. The early fullness profile felt different…

triple agonist is the most under-discussed thing on this board, which sounds obvious until you try to state the evidence for it. Kept a log specifically because there…

Question in the title, detail here: why does nobody talk about glucagon. Independent purity testing on this compound is thin compared with the older molecules, simply…

what would you tell week-1 you about glucagon, and I want the answer with the reasoning attached rather than just the conclusion. Sent a vial to Medutest out of…

stalled for 17 weeks at 2.5mg and I refuse to panic this time. I have gone back and forth on this for months. 17 weeks and 2.5mg — those are the numbers, and they are…

Title says it — 2th independent test on BCH — 97.8% on a claimed 97.5%, and the trend is the interesting part — so here is the boring supporting detail that makes it…

genuine question about phase 2 that I am slightly embarrassed to ask. If this has been answered properly somewhere, link me and I will delete. Read the phase 2 paper…

SELECT: what the trials say vs what this community says — a position I have arrived at slowly and would like tested. Why comparing across trials almost never works,…

unpopular opinion: most of what gets said here about glucagon is guesswork, and I am aware this is a minority view on this board. Where the evidence actually stands,…

Filing this under things worth writing down: 9th independent test on QYB — 97.7% on a claimed 97.0%, and the trend is the interesting part. Numbers, in the order they…

Genuine question, and the title is the question: someone explain phase 2 to me like I have not read a paper in years. Stopped at a low step because there was no reason…

26 weeks, 5kg, and dose escalation was the hard part. Same spreadsheet I have been keeping since the start, nothing retrofitted. Figures up front so nobody has to dig:…

write the concentration on the vial. that is the whole post. Two minutes of reading now saves an argument later. Quoted a figure here confidently, got asked whether it…

can we stop arguing about dose escalation until somebody posts a number. Searched first, found three threads that contradict each other, hence the post. Went up slowly,…

is it normal to get fatigue at week 5. Numbers below. Ask me the boring questions, they are the useful ones. It is a triple agonist at the GLP-1, GIP and glucagon…

Something I keep coming back to: reading triple agonist threads from 2024 and half of it aged badly. The phase 2 readout ran to 48 weeks in a few hundred participants…

hazard ratio is the most under-discussed thing on this board — a position I have arrived at slowly and would like tested. Relative risk reduction without the baseline…

Reporting in. 3 months in and triple agonist is still the thing I get wrong. The numbers the title promised, since a headline without them is worthless: 3 months.…